Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of ALD1910 (Lu AG09222) in Healthy Volunteers
NCT04197349Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Sep 2019
- Primary completion
- Aug 2020
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lu ag09222 in migraine (3 arms), sponsored by Lundbeck. Primary endpoint: Treatment-Emergent Adverse Events. Started Sep 2019; status: completed.
02
Drugs
lu ag09222
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04197349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04197349.